Gilead Sciences, headquartered in Foster City, California, employs 18,000 people and focuses on developing medicines for HIV, hepatitis, COVID-19, and cancer. Its portfolio includes numerous marketed products and several promising candidates.
GILD has been in the news recently: Gilead Sciences relies on Medicaid for approximately 22% of its U.S. sales, which may be affected by President Trump's "One Big Beautiful Bill Act," cutting over $1 trillion from Medicaid. Additionally, major stock indexes like the Dow and S&P 500 have recently seen gains of nearly 4% and have RSI readings around 75.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
